IL1B and adult-onset Still disease: Part of our dataset also preceded the European Medicines Agency’s approval of using IL-1 inhibitors to treat AOSD (canakinumab in 2016 [39], anakinra in 2018 [40]), which may explain why only 90 out of 120 patients had ever undergone IL-1 inhibition.